In this context, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines previously did not recommend SGLT2 inhibitors for kidney transplant recipients owing to insufficient evidence [10]; although recent updates have broadened the recommendations to adults with CKD [11], robust clinical data in transplant populations remain limited. The gene discussed is SLC5A2; the disease is chronic kidney disease.